Tilray announced the import of bulk medical cannabis oral solutions to its operations in the UK from its facility in Canada.
Tilray (NASDAQ:TLRY) announced the import of bulk medical cannabis oral solutions to its operations in the UK from its facility in Canada.
As quoted in the press release:
This export allows Tilray to provide authorized UK patients in need with a locally maintained supply of medical cannabis oral solutions.
“As demand ramps up in the UK, Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the UK and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
Tilray has six medical cannabis products approved for medical use in the UK that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.